1
|
Torre LA, Trabert B, DeSantis CE, Miller
KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL:
Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296.
2018. View Article : Google Scholar : PubMed/NCBI
|
2
|
Staicu CE, Predescu DV, Rusu CM, Radu BM,
Cretoiu D, Suciu N, Crețoiu SM and Voinea SC: Role of microRNAs as
clinical cancer biomarkers for ovarian cancer: A short overview.
Cells. 9:1692020. View Article : Google Scholar : PubMed/NCBI
|
3
|
Tsujioka H, Yotsumoto F, Hikita S, Ueda T,
Kuroki M and Miyamoto S: Targeting the heparin-binding epidermal
growth factor-like growth factor in ovarian cancer therapy. Curr
Opin Obstet Gynecol. 23:24–30. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Pinato DJ, Graham J, Gabra H and Sharma R:
Evolving concepts in the management of drug resistant ovarian
cancer: Dose dense chemotherapy and the reversal of clinical
platinum resistance. Cancer Treat Rev. 39:153–160. 2013. View Article : Google Scholar : PubMed/NCBI
|
5
|
Lu KH: Screening for ovarian cancer in
asymptomatic women. Jama. 319:557–558. 2018. View Article : Google Scholar : PubMed/NCBI
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Ann Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
8
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010. View
Article : Google Scholar : PubMed/NCBI
|
9
|
Deb B, Uddin A and Chakraborty S: miRNAs
and ovarian cancer: An overview. J Cell Physiol. 233:3846–3854.
2018. View Article : Google Scholar : PubMed/NCBI
|
10
|
Mandilaras V, Vernon M, Meryet-Figuiere M,
Karakasis K, Lambert B, Poulain L, Oza A and Denoyelle C: Updates
and current challenges in microRNA research for personalized
medicine in ovarian cancer. Exp Opin Biol Ther. 17:927–943. 2017.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Zhou P, Xiong T, Yao L and Yuan J:
MicroRNA-665 promotes the proliferation of ovarian cancer cells by
targeting SRCIN1. Exp Ther Med. 19:1112–1120. 2020.PubMed/NCBI
|
12
|
Wang Y, Lei X, Gao C, Xue Y, Li X, Wang H
and Feng Y: miR-506-3p suppresses the proliferation of ovarian
cancer cells by negatively regulating the expression of MTMR6. J
Biosci. 44:1262019. View Article : Google Scholar : PubMed/NCBI
|
13
|
Kavitha N, Vijayarathna S, Jothy SL, Oon
CE, Chen Y, Kanwar JR and Sasidharan S: MicroRNAs: Biogenesis,
roles for carcinogenesis and as potential biomarkers for cancer
diagnosis and prognosis. Asian Pac J Cancer Prev. 15:7489–7497.
2014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Galasso M, Sandhu SK and Volinia S:
MicroRNA expression signatures in solid malignancies. Cancer J.
18:238–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Zheng B, Liang L, Huang S, Zha R, Liu L,
Jia D, Tian Q, Wang Q, Wang C, Long Z, et al: MicroRNA-409
suppresses tumour cell invasion and metastasis by directly
targeting radixin in gastric cancers. Oncogene. 31:4509–4516. 2012.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Josson S, Gururajan M, Hu P, Shao C, Chu
GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, et al: miR-409-3p/-5p
promotes tumorigenesis, epithelial-to-mesenchymal transition, and
bone metastasis of human prostate cancer. Clin Cancer Res.
20:4636–4646. 2014. View Article : Google Scholar : PubMed/NCBI
|
17
|
Yu H, Xing H, Han W, Wang Y, Qi T, Song C,
Xu Z, Li H and Huang Y: MicroRNA-409-5p is upregulated in breast
cancer and its downregulation inhibits cancer development through
downstream target of RSU1. Tumour Biol. 39:10104283177016472017.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Zhang S, Lu Z, Unruh AK, Ivan C, Baggerly
KA, Calin GA, Li Z, Bast RC Jr and Le XF: Clinically relevant
microRNAs in ovarian cancer. Mol Cancer Res. 13:393–401. 2015.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Zhang S, Zhang X, Fu X, Li W, Xing S and
Yang Y: Identification of common differentially-expressed miRNAs in
ovarian cancer cells and their exosomes compared with normal
ovarian surface epithelial cell cells. Oncol Lett. 16:2391–2401.
2018.PubMed/NCBI
|
20
|
Koffa MD, Casanova CM, Santarella R,
Köcher T, Wilm M and Mattaj IW: HURP is part of a ran-dependent
complex involved in spindle formation. Curr Biol. 16:743–754. 2006.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Schneider MA, Christopoulos P, Muley T,
Warth A, Klingmueller U, Thomas M, Herth FJ, Dienemann H, Mueller
NS, Theis F and Meister M: AURKA, DLGAP5, TPX2, KIF11 and CKAP5:
Five specific mitosis-associated genes correlate with poor
prognosis for non-small cell lung cancer patients. Int J Oncol.
50:365–372. 2017. View Article : Google Scholar : PubMed/NCBI
|
22
|
Shi YX, Yin JY, Shen Y, Zhang W, Zhou HH
and Liu ZQ: Genome-scale analysis identifies NEK2, DLGAP5 and ECT2
as promising diagnostic and prognostic biomarkers in human lung
cancer. Sci Rep. 7:80722017. View Article : Google Scholar : PubMed/NCBI
|
23
|
Weinberger P, Ponny SR, Xu H, Bai S,
Smallridge R, Copland J and Sharma A: Cell cycle M-phase genes are
highly upregulated in anaplastic thyroid carcinoma. Thyroid.
27:236–252. 2017. View Article : Google Scholar : PubMed/NCBI
|
24
|
Zhou Y, Yang L, Zhang X, Chen R, Chen X,
Tang W and Zhang M: Identification of potential biomarkers in
glioblastoma through bioinformatic analysis and evaluating their
prognostic value. Biomed Res Int. 2019:65815762019. View Article : Google Scholar : PubMed/NCBI
|
25
|
Zhou Z, Cheng Y, Jiang Y, Liu S, Zhang M,
Liu J and Zhao Q: Ten hub genes associated with progression and
prognosis of pancreatic carcinoma identified by co-expression
analysis. Int J Biol Sci. 14:124–136. 2018. View Article : Google Scholar : PubMed/NCBI
|
26
|
Branchi V, Garcia SA, Radhakrishnan P,
Győrffy B, Hissa B, Schneider M, Reißfelder C and Schölch S:
Prognostic value of DLGAP5 in colorectal cancer. Int J Colorectal
Dis. 34:1455–1465. 2019. View Article : Google Scholar : PubMed/NCBI
|
27
|
Liao W, Liu W, Yuan Q, Liu X, Ou Y, He S,
Yuan S, Qin L, Chen Q, Nong K, et al: Silencing of DLGAP5 by siRNA
significantly inhibits the proliferation and invasion of
hepatocellular carcinoma cells. PLoS One. 8:e807892013. View Article : Google Scholar : PubMed/NCBI
|
28
|
Kuo TC, Chang PY, Huang SF, Chou CK and
Chao CCK: Knockdown of HURP inhibits the proliferation of
hepacellular carcinoma cells via downregulation of gankyrin and
accumulation of p53. Biochem Pharmacol. 83:758–768. 2012.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Zhang X, Pan Y, Fu H and Zhang J:
Nucleolar and spindle associated protein 1 (NUSAP1) inhibits cell
proliferation and enhances susceptibility to epirubicin in invasive
breast cancer cells by regulating cyclin D kinase (CDK1) and DLGAP5
expression. Med Sci Monit. 24:8553–8564. 2018. View Article : Google Scholar : PubMed/NCBI
|
30
|
Zeppernick F and Meinhold-Heerlein I: The
new FIGO staging system for ovarian, fallopian tube, and primary
peritoneal cancer. Arch Gynecol Obstet. 290:839–842. 2014.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Rosen DG, Yang G, Liu G, Mercado-Uribe I,
Chang B, Xiao XS, Zheng J, Xue FX and Liu J: Ovarian cancer:
Pathology, biology, and disease models. Front Biosci (Landmark Ed).
14:2089–2102. 2009. View
Article : Google Scholar : PubMed/NCBI
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Xu X, Chen H, Lin Y, Hu Z, Mao Y, Wu J, Xu
X, Zhu Y, Li S, Zheng X and Xie L: MicroRNA-409-3p inhibits
migration and invasion of bladder cancer cells via targeting c-met.
Mol Cells. 36:62–68. 2013. View Article : Google Scholar : PubMed/NCBI
|
34
|
Wan L, Zhu L, Xu J, Lu B, Yang Y, Liu F
and Wang Z: MicroRNA-409-3p functions as a tumor suppressor in
human lung adenocarcinoma by targeting c-met. Cell Physiol Biochem.
34:1273–1290. 2014. View Article : Google Scholar : PubMed/NCBI
|
35
|
Bai R, Weng C, Dong H, Li S, Chen G and Xu
Z: MicroRNA-409-3p suppresses colorectal cancer invasion and
metastasis partly by targeting GAB1 expression. Int J Cancer.
137:2310–2322. 2015. View Article : Google Scholar : PubMed/NCBI
|
36
|
Zhang G, Liu Z, Xu H and Yang Q:
miR-409-3p suppresses breast cancer cell growth and invasion by
targeting Akt1. Biochem Biophys Res Commun. 469:189–195. 2016.
View Article : Google Scholar : PubMed/NCBI
|
37
|
Cao GH, Sun XL, Wu F, Chen WF, Li JQ and
Hu WC: Low expression of miR-409-3p is a prognostic marker for
breast cancer. Eur Rev Med Pharmacol Sci. 20:3825–3829.
2016.PubMed/NCBI
|
38
|
Cao Y, Zhang L, Wei M, Jiang X and Jia D:
MicroRNA-409-3p represses glioma cell invasion and proliferation by
targeting high-mobility group nucleosome-binding domain 5. Oncol
Res. 25:1097–1107. 2017. View Article : Google Scholar : PubMed/NCBI
|
39
|
Prakash R, John AA and Singh D: miR-409-5p
negatively regulates Wnt/Beta catenin signaling pathway by
targeting Lrp-8. J Cell Physiol. 234:23507–23517. 2019. View Article : Google Scholar : PubMed/NCBI
|
40
|
Li C, Nie H, Wang M, Su L, Li J, Yu B, Wei
M, Ju J, Yu Y, Yan M, et al: MicroRNA-409-3p regulates cell
proliferation and apoptosis by targeting PHF10 in gastric cancer.
Cancer Lett. 320:189–197. 2012. View Article : Google Scholar : PubMed/NCBI
|
41
|
Zhang J, Hou W, Jia J, Zhao Y and Zhao B:
miR-409-3p regulates cell proliferation and tumor growth by
targeting E74-like factor 2 in osteosarcoma. FEBS Open Bio.
7:348–357. 2017. View Article : Google Scholar : PubMed/NCBI
|
42
|
Zhao Z, Yang F, Liu Y, Fu K and Jing S:
MicroRNA-409-3p suppresses cell proliferation and cell cycle
progression by targeting cyclin D2 in papillary thyroid carcinoma.
Oncol Lett. 16:5237–5242. 2018.PubMed/NCBI
|
43
|
Ma Z, Li Y, Xu J, Ren Q, Yao J and Tian X:
MicroRNA-409-3p regulates cell invasion and metastasis by targeting
ZEB1 in breast cancer. IUBMB Life. 68:394–402. 2016. View Article : Google Scholar : PubMed/NCBI
|
44
|
Chen H and Dai J: miR-409-3p suppresses
the proliferation, invasion and migration of tongue squamous cell
carcinoma via targeting RDX. Oncol Lett. 16:543–551.
2018.PubMed/NCBI
|
45
|
Wu L, Zhang Y, Huang Z, Gu H, Zhou K, Yin
X and Xu J: MiR-409-3p inhibits cell proliferation and invasion of
osteosarcoma by targeting zinc-finger E-box-binding homeobox-1.
Front Pharmacol. 10:1372019. View Article : Google Scholar : PubMed/NCBI
|
46
|
Santarella RA, Koffa MD, Tittmann P, Gross
H and Hoenger A: HURP wraps microtubule ends with an additional
tubulin sheet that has a novel conformation of tubulin. J Mol Biol.
365:1587–1595. 2007. View Article : Google Scholar : PubMed/NCBI
|
47
|
Hsu JM, Lee YC, Yu CT and Huang CY: Fbx7
functions in the SCF complex regulating Cdk1-cyclin
B-phosphorylated hepatoma up-regulated protein (HURP) proteolysis
by a proline-rich region. J Biol Chem. 279:32592–32602. 2004.
View Article : Google Scholar : PubMed/NCBI
|
48
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Ann Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
49
|
Ganju A, Khan S, Hafeez BB, Behrman SW,
Yallapu MM, Chauhan SC and Jaggi M: miRNA nanotherapeutics for
cancer. Drug Discov Today. 22:424–432. 2017. View Article : Google Scholar : PubMed/NCBI
|
50
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
51
|
Bader AG, Brown D and Winkler M: The
promise of microRNA replacement therapy. Cancer Res. 70:7027–7030.
2010. View Article : Google Scholar : PubMed/NCBI
|